Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:ABT

Abbott Labs (ABT)

116.64
+2.50 (2.19%)
as of Aug 21, 2026, 8:00:00 pm Market Open.
356 watching
0
Investor Insights
star iconAug 23, 2026, 12:00 am

This summary was created by AI, based on 13 opinions in the last 12 months.

Abbott Labs (ABT) has faced significant challenges over the past year, with a general consensus indicating that its stock has been struggling, down approximately 30%. Analysts have noted that despite the recent acquisition and overall strength in its diagnostics and medical devices segments, growth has not met expectations, leading to lowered guidance and a decline in share prices. The stock trades at a relatively attractive price-to-earnings ratio, which many believe does not fully reflect its growth potential, especially in light of the company's new cancer treatment acquisition. While some experts maintain a bullish stance, citing the company’s diversified product portfolio and strong balance sheet, caution is advised as the stock continues to experience significant volatility in the market. Overall, while Abbott Labs possesses long-term growth potential, particularly in the healthcare sector, it remains under pressure due to recent performance setbacks and ongoing competition.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
ALC,ALC
BUY

The pharmaceutical sector has not gone anywhere for decades. Now they are starting to act like value stocks. Owns other pharma companies like J&J and Senofi. Now is a good time to put pharma stocks to your porfolio.

PAST TOP PICK
(A Top Pick Jun 24/20, Up 29%) Recently revised guidance by 10-15% of earnings, as they saw a sharp decline in Covid testing. Still growing earnings in double digits. Medical devices and diagnostics are still doing well. Dividend is not high, but increased consistently. She's buying for new clients on this pullback.
DON'T BUY

Fine managers and company. They hold the record in raising dividends by 48 straight years. Super stable. They do diagnostics, nutrition, though spun off a business to Abbvie about 8 years ago. They trade in mid-20sx in PE, and grow by a decent 10%. Problem is this high valuation, so he'd look elsewhere in this space, Abbvie, which he owns.

TOP PICK
Two profit centres are the diagnostic testing and medical devices businesses, accounting for 75% of their operating profit. He's long liked this. Last week, they announced that their Covid-testing business has fallen off with the reopening, so shares sold off. But he sees long-term growth. It trades below 23x earnings in line with peers and market. ABT is defensive with strong growth. Offers good US exposure to healthcare. (Analysts’ price target is $123.33)
DON'T BUY
It is trading at around 34x earnings. It hasn't done much in the last year. It is where it was last year, maybe 10% up. Compared to the rest of the market, it hasn't moved. Big pharma was out of favour a couple years ago. This has now come back into favour. It is fully valued now. Has had a wonderful run. A little expensive.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Oct 08/20, Up 0.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has triggered its stop at $109. To remain disciplined, we recommend covering the balance of the holding. Combined with the previous recommendation to cover 50% of the position, this will result in a net investment gain of 9%.
BUY

ABT vs. MRK Both are great companies. ABT is the leading supplier of products to the medical industry. Merck has incredible products as a global pharmaceutical company. You could hold either.

BUY

ABT vs. JNJ Healthcare is in a more defensive space, moving up during the pandemic. Likes both. JNJ has a fairly nice dividend at 2.5%. 18x forward earnings for 8% growth. Performing decently, but underperforming the S&P. ABT is more in medical devices. Marginally underperforming since last March. 22x earnings with a higher growth rate of 14%. Bit more torque with ABT, and they're also in the Covid detection space. If he had to choose, it would be ABT.

TOP PICK
A diversified US healthcare company in diagnostics, branded pharmaceuticals, nutrition and medical devices. It produces a lot of Covid-testing kits, which has boosted their bottom line. They can maintain double-digit earnings growth based on growth in medical devices. For instance, a diagnostic kit for diabetes (don't need to prick finger) is popular. About 40% of products are sold in emerging markets. They increase their dividend annually, for the past 49 years. Pays a 1.5% dividend. This has pulled back, so buy now. (Analysts’ price target is $133.26)
BUY
They report Tuesday. They've done great work with their Covid test that they will likely hit it out of the park.
BUY

Liked BSX better in the past than today. If there were a recession, they'd need more capital. Remains a very fine company as to products. Volumes in medical devices are not recovering as he expected. He owns ABT instead, a diversified player with a very strong balance sheet.

BUY
It has done quite well compared to other healthcare stocks. They have had a lot of regulatory approvals and had strong earnings in Q2-20. In May the sector can do quite well, seasonally. Given its success across its divisions, he would say it is a good stock to hold even before its seasonal period.
BUY
This can still go higher. No need to worry about their diabetes franchise.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Oct 08/20, Up 17.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has achieved its $128 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $97) to the original recommended price level at $109.
BUY
Diversified medical device company. Acquisitions increased leverage, but they've paid it down. Less focused on slower growth business, more on devices. Great quality. Positive results from Covid testing have exceeded estimates.
Showing 76 to 90 of 223 entries